Abstract |
Results of an open, phase II clinical trial on therapy with an iv IgG preparation in patients with primary antibody-deficiency syndromes are reported. Three hundred infusions of the product, an intact monomeric IgG preparation, were given to 16 patients for an average of 14 (+/- 0.7) months, the dose being 220 (+/- 26.9) mg/kg/month. Only two minor adverse reactions occurred. This preparation did not produce transient leukopenia on infusion. Preinfusion serum IgG levels increased continuously in the course of treatment (average values: 325 +/- 51 at the beginning of therapy, 438 +/- 59 at 6 months, 568 +/- 75 at 12 months, 631 +/- 52 at the end of treatment). The infusions were well accepted and well tolerated by the patients, and the clinical efficacy was highly superior to intramuscular immunoglobulin.
|
Authors | M M Eibl, L Cairns, F S Rosen |
Journal | Clinical immunology and immunopathology
(Clin Immunol Immunopathol)
Vol. 31
Issue 1
Pg. 151-60
(Apr 1984)
ISSN: 0090-1229 [Print] United States |
PMID | 6421524
(Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Child
- Child, Preschool
- Clinical Trials as Topic
- Dose-Response Relationship, Immunologic
- Female
- Humans
- Immunization, Passive
(adverse effects)
- Immunoglobulin G
(administration & dosage, biosynthesis)
- Immunologic Deficiency Syndromes
(blood, immunology, therapy)
- Infusions, Parenteral
- Long-Term Care
- Male
- Middle Aged
|